THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS.

Siddiqui M.; Bhoday J.; Chand M.; Freudian M.; Tekkis P.; Lim E.; Abulafi A.; Brown G.

首页> 外文期刊>Diseases of the Colon and Rectum >THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS.

【24h】

THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS.

机译：由KRAS和TP53突变定义的无细胞循环肿瘤DNA（CTDNA）在大肠癌复发率评估中的作用：一项meta分析。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Diseases of the Colon and Rectum》 |2016年第5期|共2页
作者
Siddiqui M.; Bhoday J.; Chand M.; Freudian M.; Tekkis P.; Lim E.; Abulafi A.; Brown G.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. 中国乳腺癌患者循环肿瘤DNA中TP53突变的临床特征及预后价值 [J] . 易宗毕, 马飞, 荣国华, 癌症（英文版） . 2021,第005期
2. THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS. [J] . Siddiqui M., Bhoday J., Chand M., Diseases of the Colon and Rectum . 2016,第5期

机译：由KRAS和TP53突变定义的无细胞循环肿瘤DNA（CTDNA）在大肠癌复发率评估中的作用：一项meta分析。
3. Preoperative Detection of KRAS G12D Mutation in Cell-free Circulating Tumor DNA is a Powerful Predictor for Early Recurrence of Resectable Pancreatic Ductal Adenocarcinoma Patients [J] . Shi X. H., Guo S. W., Shen J., Pancreas . 2019,第10期

机译：在无细胞循环肿瘤DNA中的KRAS G12D突变的术前检测是可重置胰腺导管腺癌患者的早期复发的强力预测因子
4. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations [J] . Esposito Angela, Criscitiello Carmen, Trapani Dario, Current oncology reports. . 2017,第1a2期

机译：“液体活组织检查”，循环肿瘤细胞和循环无细胞肿瘤DNA在肺癌诊断和抗性突变鉴定中的新兴作用
5. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
6. Glucose deprivation selects for KRAS and BRAF mutations in colorectal cancer. [D] . Yun, Jihye. 2009

机译：葡萄糖剥夺选择结直肠癌中的KRAS和BRAF突变。
7. TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer [O] . Silvia R. Vitale, Floris H. Groenendijk, Ronald van Marion, 2020

机译：血清循环性无细胞肿瘤DNA中的TP53突变作为高级浆液性卵巢癌的纵向生物标记。
8. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype [O] . N Tarazona Llavero, F. Gimeno-Valiente, V. Gambardella, 2019

机译：循环肿瘤DNA（CTDNA）突变跟踪检测局部结直肠癌（CRC）患者的最小残留疾病（MRD），并鉴定出高度复发风险的疾病，无论阶段，缺乏CDX2表达和CMS亚型

THE ROLE OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) DEFINED BY KRAS AND TP53 MUTATIONS IN THE ASSESSMENT OF COLORECTAL CANCER RECURRENCE: A META-ANALYSIS.

著录项

相似文献

相关主题

期刊订阅